Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Gains from Sales and Divestitures (2020 - 2025)

Historic Gains from Sales and Divestitures for Xtant Medical Holdings (XTNT) over the last 6 years, with Q3 2025 value amounting to $1.2 million.

  • Xtant Medical Holdings' Gains from Sales and Divestitures fell 2207.99% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 2207.99%. This contributed to the annual value of $1.3 million for FY2024, which is 1466.65% down from last year.
  • Latest data reveals that Xtant Medical Holdings reported Gains from Sales and Divestitures of $1.2 million as of Q3 2025, which was down 2207.99% from $386624.0 recorded in Q2 2025.
  • Over the past 5 years, Xtant Medical Holdings' Gains from Sales and Divestitures peaked at $1.5 million during Q4 2023, and registered a low of $22245.0 during Q1 2023.
  • For the 5-year period, Xtant Medical Holdings' Gains from Sales and Divestitures averaged around $611811.6, with its median value being $349572.0 (2021).
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first tumbled by 9091.01% in 2023, then skyrocketed by 53981.57% in 2024.
  • Quarter analysis of 5 years shows Xtant Medical Holdings' Gains from Sales and Divestitures stood at $782596.0 in 2021, then soared by 91.72% to $1.5 million in 2022, then increased by 2.39% to $1.5 million in 2023, then decreased by 14.67% to $1.3 million in 2024, then fell by 11.91% to $1.2 million in 2025.
  • Its Gains from Sales and Divestitures was $1.2 million in Q3 2025, compared to $386624.0 in Q2 2025 and $44496.0 in Q1 2025.